Inactive Instrument

News Aquinox Pharmaceuticals Inc Nasdaq

Equities

US03842B1017

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Neurogene : ASGCT NGN-401 Clinical Safety Poster	May. 07	PU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting	May. 07	BU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	May. 07	CI
Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	Apr. 29	MT
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	Apr. 22	BU
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
William Blair Initiates Neurogene With Outperform Rating	Mar. 21	MT
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	Mar. 18	BU
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04	BU
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04	CI
Neurogene to Participate in Upcoming Investor Conferences	Feb. 29	BU
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	Feb. 21	CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	Jan. 17	CI
Neurogene Names Julie Jordan as Chief Medical Officer	Jan. 16	MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16	BU
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16	CI
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	Jan. 08	MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	Jan. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aquinox Pharmaceuticals Inc Nasdaq

Equities

US03842B1017

Summary

Filters